Kodiak Sciences Inc. (KOD)
Stock Price:
$97.74 USD
1.08 (1.12%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
4.37B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-78.39M |
| Shares Out |
44.71M |
| EPS (ttm) |
-1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$97.74 |
| Previous Close |
$96.66 |
| Change ($) |
1.08 |
| Change (%) |
1.12% |
| Day's Open |
96.95 |
| Day's Range |
94.84 - 102.74 |
| Day's Volume |
463,152 |
| 52-Week Range |
18.52 - 102.74 |
More Stats
| Market Cap |
4.37B |
| Enterprise Value |
3.95B |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.71M |
| Float |
37.51M |
| EPS (basic) |
-1.85 |
| EPS (diluted) |
-1.88 |
| FCF / Share |
-1.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.71M |
| Short Ratio |
12.34 |
| Short % of Float |
9.88% |
| Beta |
1.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
13.97 |
| Revenue |
n/a |
| Operating Income |
-81.42M |
| Net Income |
-78.39M |
| Free Cash Flow |
-51.39M |
| Net Cash |
415.55M |
| Net Cash / Share |
9.29 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-20.05% |
| ROE |
-41.34% |
| ROIC |
-61.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$81.50*
(-16.62% downside)
Low
52.0
Current: $97.74
High
115.0
Target: 81.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -49.19 | -26.37 | -25.52 | -17.15 |
| Net Income | -47.37 | -41.44 | -27.94 | -17.13 |
| Shares Outstanding | 37.85 | 14.98 | 7.52 | 7.21 |
| Earnings Per Share | -1.25 | -2.77 | -3.72 | -2.38 |
| Operating Cash Flow | -39.15 | -29.03 | -17.66 | -16.05 |
| Capital Expenditures | -0.44 | -0.58 | -0.21 | -0.77 |
| Free Cash Flow | -39.58 | -29.61 | -17.86 | -16.82 |
| Cash & Equivalents | 337 | 88.39 | 1.54 | 9.76 |
| Total Debt | 1.94 | - | 9.92 | 0.10 |
| Net Cash / Debt | 335 | 88.39 | -8.39 | 9.66 |
| Assets | 359 | 92.19 | 3.24 | 12.11 |
| Liabilities | 13.51 | 5.36 | 21.97 | 3.18 |
| Book Value | 345 | 86.83 | -68.74 | -41.08 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kodiak Sciences Inc. |
| Country |
United States |
| Employees |
48 |
| CEO |
Victor Perlroth |
Stock Information
| Ticker Symbol |
KOD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KOD |
| IPO Date |
October 4, 2018 |
Description
Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.